Breaking News Instant updates and real-time market news.

NKTR

Nektar

$20.04

1.34 (7.17%)

, LLY

Eli Lilly

$113.56

0.73 (0.65%)

11:56
11/10/19
11/10
11:56
11/10/19
11:56

Nektar presents updated results from Phase 1a study of NKTR-358

Nektar Therapeutics (NKTR) announced updated results from the first-in-human Phase 1a study of NKTR-358, a novel T regulatory cell stimulator in development for the treatment of autoimmune and other chronic inflammatory conditions. The data, which were presented at the 2019 Annual Meeting of the American College of Rheumatology in Atlanta, show that treatment with NKTR-358 led to a marked and selective dose-dependent expansion in the numbers and proliferative capacity of FoxP3+CD25bright Treg cells, and a measurable activation of Treg cells. These data are a continuation of initial results reported at 2019 Annual European Congress of Rheumatology in June 2019. NKTR-358 is designed to treat autoimmune and inflammatory conditions by correcting the immune system imbalance that results from reduced numbers and impaired function of immune-regulating Treg cells. NKTR-358 works by targeting the interleukin-2 receptor complex to stimulate the proliferation and activation of Treg cells. NKTR-358 was discovered by Nektar and is being co-developed and commercialized in partnership with Eli Lilly (LLY). "We're pleased to report that final results from our first-in-human Phase 1a study continue to support the positive safety and tolerability profile of NKTR-358, while reinforcing its selective and measurable impact on the numbers, expansion and activation of regulatory T cells or Tregs," said Brian Kotzin, M.D., senior VP, Clinical Development and NKTR-358 Program Lead at Nektar. "Autoimmune and inflammatory diseases are marked by an imbalance in the body's self-tolerance and self-regulatory immune pathways, and the ability of NKTR-358 to expand functional Tregs could help restore normal balance. The results support further studies into the potential of NKTR-358 as a treatment for several types of immune-mediated disorders."

NKTR

Nektar

$20.04

1.34 (7.17%)

LLY

Eli Lilly

$113.56

0.73 (0.65%)

  • 10

    Nov

  • 30

    Jan

NKTR Nektar
$20.04

1.34 (7.17%)

10/23/19
OPCO
10/23/19
INITIATION
Target $18
OPCO
Perform
Nektar initiated with a Perform at Oppenheimer
Oppenheimer analyst Jay Olson initiated coverage of Nektar with a Perform rating and $18 price target.
10/23/19
OPCO
10/23/19
INITIATION
Target $18
OPCO
Perform
Oppenheimer starts Nektar at Perform, calls shares fairy valued
Oppenheimer analyst Jay Olson initiated coverage of Nektar with a Perform rating and $18 price target. The shares are fairly valued at current levels, representing a "reasonable risk-reward balance" given Nektar's dependence on bempeg combination trials and potential upside from other drug candidates, Olson tells investors in a research note. The analyst thinks bempeg has a "below-average probability of success.:
10/24/19
10/24/19
INITIATION

Fly Intel: Top five analyst initiations
Catch up on today's top five analyst initiations with this list compiled by The Fly: 1. Peloton (PTON) initiated with an Outperform at Bernstein. 2. Lyft (LYFT) initiated with an Equal Weight at Morgan Stanley. 3. Nektar (NKTR) initiated with a Perform at Oppenheimer. 4. Kellogg (K) initiated with an In Line at Evercore ISI. 5. Pitney Bowes (PBI) initiated with a Buy at National Securities. This list is just a portion of The Fly's analyst coverage. To see The Fly's full Street Research coverage, click here.
11/07/19
PIPR
11/07/19
NO CHANGE
Target $35
PIPR
Overweight
Nektar price target lowered to $35 from $50 at Piper Jaffray
Piper Jaffray analyst Tyler Van Buren lowered his price target for Nektar Therapeutics (NKTR) to $35 from $50 citing trial timeline delays following the company's Q3 results. The analyst, however, keeps an Overweight rating on the shares. Three of six planned registrational trials are ongoing with partner Bristol-Myers (BMY), and management on the call updated the timelines for topline readouts in these trials, which are delayed approximately a year, says Van Buren. He looks forward to the melanoma/PIVOT-02 cohort update at SITC this weekend and is "encouraged to see more of the pipeline advance into clinical development," saying Nektar continues to diversify beyond bempeg.
LLY Eli Lilly
$113.56

0.73 (0.65%)

09/09/19
PIPR
09/09/19
NO CHANGE
Target $85
PIPR
Neutral
Lilly's 'impressive update' raised bar higher for Blueprint, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond said he thinks Eli Lilly (LLY) issued an "impressive update" on selpercatinib at the World Lung meeting, raising the bar for Blueprint Medicines' (BPMC) pralsetinib "meaningfully higher." While selpercatinib's "best-in-class" ORR was maintained, initial durability data could be upwards of 50% better than that of pralsetinib, according to Raymond. While cautioning that his comparison is highly preliminary, Raymond said he worries that LOXO-292's superiority gap against pralsetinib "may be widening." He keeps a Neutral rating on Blueprint shares, which are down about 3% in morning trading to $75.89.
09/25/19
PIPR
09/25/19
NO CHANGE
Target $81
PIPR
Overweight
AbbVie survey supports above-consensus estimates, says Piper Jaffray
Piper Jaffray analyst Christopher Raymond keeps an Overweight rating on AbbVie (ABBV) shares with an $81 price target following a new rheumatologist survey by his firm's partners Spherix Global Insights. The survey indicates "robust" expectations for the company's oral JAK1 inhibitor Rinvoq, Raymond tells investors in a research note. Rheumatologists project that in six months, Rinvoq will leapfrog Eli Lilly's (LLY) Olumiant to become the second-most prescribed JAK with 5% share, says the analyst, citing the survey. He believes this supports his above-consensus Rinvoq revenue estimates.
10/16/19
BOFA
10/16/19
INITIATION
Target $133
BOFA
Buy
Eli Lilly reinstated with a Buy at BofA/Merrill
BofA/Merrill analyst Geoff Meacham reinstated coverage of Eli Lilly with a Buy rating and $133 price target. The analyst sees the company's "high quality, differentiated growth and modest expectations for added pipeline value" as compelling.
11/06/19
LEER
11/06/19
NO CHANGE
LEER
Outperform
ArQule data for ARQ 531 'continue to look strong,' says SVB Leerink
SVB Leerink analyst Jonathan Chang said a "positive update" on the Phase 1 study of ARQ 531 in B-cell malignancies was among the abstracts published ahead of the American Society of Hematology, or ASH, annual meeting. The abstract highlights new partial responses achieved in the "short" window between the European Hematology Association update and the ASH abstract submission deadline, noted Chang, who contends that the data "continue to look strong" for the ArQule (ARQL) drug. The analyst, who also thinks that early data reported by Eli Lilly (LLY) will "intensify investor discussion on the competitive landscape for ARQ 531," still believes ArQule remains in the lead and he reiterates an Outperform rating on the shares.

TODAY'S FREE FLY STORIES

VRTX

Vertex

$215.00

4.99 (2.38%)

05:23
11/20/19
11/20
05:23
11/20/19
05:23
Hot Stocks
Vertex says CEPS approved national reimbursement of ORKAMBI »

Vertex Pharmaceuticals…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 19

    Mar

MALRF

Mineral Resources

$0.00

(0.00%)

05:22
11/20/19
11/20
05:22
11/20/19
05:22
Downgrade
Mineral Resources rating change  »

Mineral Resources…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CS

Credit Suisse

$13.06

0.05 (0.38%)

05:21
11/20/19
11/20
05:21
11/20/19
05:21
Upgrade
Credit Suisse rating change  »

Credit Suisse upgraded to…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CRH

CRH

$37.46

0.07 (0.19%)

05:19
11/20/19
11/20
05:19
11/20/19
05:19
Downgrade
CRH rating change  »

CRH downgraded to Reduce…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CEO

Cnooc

$151.76

-0.6 (-0.39%)

05:19
11/20/19
11/20
05:19
11/20/19
05:19
Hot Stocks
CNOOC says Caofeidian 11-1/11-6 oilfield project starts production »

CNOOC announced that…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

VVCIF

Vivo Cannabis

$0.00

(0.00%)

05:18
11/20/19
11/20
05:18
11/20/19
05:18
Downgrade
Vivo Cannabis rating change  »

Vivo Cannabis downgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

DIS

Disney

$148.33

0.68 (0.46%)

05:17
11/20/19
11/20
05:17
11/20/19
05:17
Recommendations
Disney analyst commentary  »

Imperial Capital ups…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

NTAP

NetApp

$62.88

-0.58 (-0.91%)

, GOOG

Alphabet

$1,314.71

-3.74 (-0.28%)

05:16
11/20/19
11/20
05:16
11/20/19
05:16
Hot Stocks
NetApp, Google Cloud advance strategic partnership »

NetApp (NTAP) and Google…

NTAP

NetApp

$62.88

-0.58 (-0.91%)

GOOG

Alphabet

$1,314.71

-3.74 (-0.28%)

GOOGL

Alphabet Class A

$1,312.59

-7.58 (-0.57%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 12

    Dec

BA

Boeing

$366.93

-2.57 (-0.70%)

05:15
11/20/19
11/20
05:15
11/20/19
05:15
Earnings
Boeing, Emirates announce order for 30 787 Dreamliner planes »

Boeing and Emirates…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

AVAV

AeroVironment

$60.83

-0.81 (-1.31%)

05:14
11/20/19
11/20
05:14
11/20/19
05:14
Recommendations
AeroVironment analyst commentary  »

AeroVironment should…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 03

    Dec

  • 09

    Dec

NXTC

NextCure

$36.02

-0.23 (-0.63%)

05:11
11/20/19
11/20
05:11
11/20/19
05:11
Recommendations
NextCure analyst commentary  »

NextCure price target…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

PCG

PG&E

$6.85

-0.22 (-3.11%)

05:10
11/20/19
11/20
05:10
11/20/19
05:10
Hot Stocks
PG&E shutting off power for about 150,000 customers in CA for PSPS »

Pacific Gas and Electric…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 07

    Jan

ZBRA

Zebra Technologies

$236.17

1.73 (0.74%)

05:09
11/20/19
11/20
05:09
11/20/19
05:09
Recommendations
Zebra Technologies analyst commentary  »

Zebra Technologies price…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

CBOE

Cboe Global Markets

$122.53

2.01 (1.67%)

, TW

Tradeweb Markets

$43.26

-0.29 (-0.67%)

05:07
11/20/19
11/20
05:07
11/20/19
05:07
Downgrade
Cboe Global Markets, Tradeweb Markets rating change  »

Cboe Global Markets…

CBOE

Cboe Global Markets

$122.53

2.01 (1.67%)

TW

Tradeweb Markets

$43.26

-0.29 (-0.67%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

TW

Tradeweb Markets

$43.26

-0.29 (-0.67%)

05:03
11/20/19
11/20
05:03
11/20/19
05:03
Upgrade
Tradeweb Markets rating change  »

Tradeweb Markets upgraded…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BCO

Brink's

$90.04

0.515 (0.58%)

04:59
11/20/19
11/20
04:59
11/20/19
04:59
Initiation
Brink's initiated  »

Brink's initiated…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

BRY

Berry Petroleum

$8.90

-2.405 (-21.27%)

04:58
11/20/19
11/20
04:58
11/20/19
04:58
Downgrade
Berry Petroleum rating change  »

Berry Petroleum…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

KLAC

KLA-Tencor

$176.04

-0.95 (-0.54%)

04:55
11/20/19
11/20
04:55
11/20/19
04:55
Initiation
KLA-Tencor initiated  »

KLA-Tencor initiated with…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 09

    Dec

CBAY

CymaBay

$5.49

0.03 (0.55%)

, ALXN

Alexion

$110.65

2.71 (2.51%)

04:55
11/20/19
11/20
04:55
11/20/19
04:55
Conference/Events
Stifel to hold a conference »

Healthcare Conference…

CBAY

CymaBay

$5.49

0.03 (0.55%)

ALXN

Alexion

$110.65

2.71 (2.51%)

CBIO

Catalyst Biosciences

$5.18

-0.105 (-1.99%)

QURE

uniQure

$54.98

1.87 (3.52%)

GTHX

G1 Therapeutics

$22.72

0.32 (1.43%)

HZNP

Horizon Pharma

$30.49

-0.23 (-0.75%)

IONS

Ionis Pharmaceuticals

$58.04

0.27 (0.47%)

SILK

Silk Road Medical

$36.28

-1.27 (-3.38%)

SAGE

Sage Therapeutics

$147.89

2.28 (1.57%)

KIN

Kindred Biosciences

$7.48

0.14 (1.91%)

ACOR

Acorda Therapeutics

$1.58

-0.04 (-2.48%)

MASI

Masimo

$153.27

3.34 (2.23%)

IRIX

Iridex

$1.91

-0.12 (-5.91%)

BSX

Boston Scientific

$42.63

0.34 (0.80%)

PRVL

Prevail Therapeutics

$12.49

1.45 (13.13%)

SUPN

Supernus

$21.76

-0.28 (-1.27%)

EVLO

Evelo Biosciences

$5.64

-0.6 (-9.62%)

HRC

Hill-Rom

$107.23

2.64 (2.52%)

SVRA

Savara

$0.91

0.0064 (0.71%)

AERI

Aerie Pharmaceuticals

$18.85

-0.16 (-0.84%)

TNDM

TNDM

CERS

Cerus

$4.32

-0.055 (-1.26%)

SBBP

Strongbridge Biopharma

$1.49

0.025 (1.71%)

INGN

Inogen

$71.23

1.46 (2.09%)

ALDX

Aldeyra

$6.02

0.16 (2.73%)

ZGNX

Zogenix

$45.70

0.71 (1.58%)

VIVE

Viveve

$3.33

0.31 (10.26%)

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 20

    Nov

  • 07

    Dec

  • 12

    Dec

  • 16

    Dec

GLOP

GasLog Partners

$15.49

-1.01 (-6.12%)

04:55
11/20/19
11/20
04:55
11/20/19
04:55
Conference/Events
GasLog Partners management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

  • 22

    Nov

ECL

Ecolab

$189.44

-1.84 (-0.96%)

04:55
11/20/19
11/20
04:55
11/20/19
04:55
Conference/Events
Ecolab management to meet with Jefferies »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

  • 21

    Nov

MMI

Marcus & Millichap

$35.91

0.17 (0.48%)

04:55
11/20/19
11/20
04:55
11/20/19
04:55
Conference/Events
Marcus & Millichap management to meet with JMP Securities »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

PSNL

Personalis

$8.89

(0.00%)

04:55
11/20/19
11/20
04:55
11/20/19
04:55
Conference/Events
Personalis management to meet with Oppenheimer »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

AMSF

Amerisafe

$67.03

1.54 (2.35%)

04:55
11/20/19
11/20
04:55
11/20/19
04:55
Conference/Events
Amerisafe management to meet with B. Riley FBR »

Meetings to be held in…

03/08/13
Wedge Partners
03/08/13
Credit Suisse
03/06/13
Citigroup
03/06/13
Barclays

See Street Research during your Free Trial

  • 20

    Nov

04:55
11/20/19
11/20
04:55
11/20/19
04:55
Conference/Events
Clarion Events to hold a conference »

PowerGen International to…

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.